BRCA1 and cancer: Co-occurrence of mutations that increase immunogenicity (e.g., BRCA1) with those enabling immune escape (e.g., CASP8) suggests a model of cancer progression where immune-mediated selection is a later event, in the setting of an otherwise immunogenic population.